drugset / Trial / NCT06154291
FIH XON7 in Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D.
Timeline
- Start
- 2023-11-14
- Primary completion
- 2026-12
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XON7 | Unknown | 1.5 mg/kg | Intravenous |
| Subject | XON7 | Unknown | 3 mg/kg | Intravenous |
| Subject | XON7 | Unknown | 6 mg/kg | Intravenous |
| Subject | XON7 | Unknown | 12 mg/kg | Intravenous |
| Subject | XON7 | Unknown | 16 mg/kg | Intravenous |
| Subject | XON7 | Unknown | 20 mg/kg | Intravenous |